REG - ValiRx PLC - Launch of Broker Offer

ValiRxAnnouncement

13/01/2023 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230113:nRSM6178Ma&default-theme=true

RNS Number : 6178M  ValiRx PLC  13 January 2023

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE "ANNOUNCEMENT") IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA,
AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
JURISDICTION.

THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION,
RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE
ACQUIRE ANY SECURITIES OF THE COMPANY.

ValiRx PLC

 

("ValiRx" or "Company")

 

Launch of Broker Offer to raise a maximum of £500,000

·    ValiRx (AIM: VAL) announces a Broker Offer through Turner Pope
Investments (TPI) Limited ("TPI").

·    The Issue Price of the Broker Offer is 11 pence per New Ordinary
Share.

·    Every 4 (four) Broker Offer shares issued will have 1 (one) Fundraise
Warrant attached, exercisable at 14 pence per Fundraise Warrant, for a period
of 36 months from admission of the Broker Offer shares.

·    The Broker Offer is for a maximum of £500,000.

·    Existing Shareholders or other interested parties who wish to
register their interest in participating in the Broker Offer should click on
the following TPI platform link:  ValiRx - TPI Broker Offer
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fforms.office.com%2Fe%2F7RAikAA4ce&data=05%7C01%7CAndy.Thacker%40TurnerPope.com%7C661a3e2bef604db39a3708daf4bce817%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638091389746329981%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=UwbJzJD9Jblz9Yk%2FAvdTe1%2FbbvSZ9HZbm1fYBZRS0vk%3D&reserved=0)
(URL: https://forms.office.com/e/7RAikAA4ce)

·    All bids communicated to TPI under the Broker Offer are subject to
review and acceptance by the Company and TPI and priority will be given to
Existing Shareholders in the event of oversubscription.

·    The Broker Offer remains open until 5 p.m. on Monday, 16 January
2023.

·    All Broker Offer Shares will be allocated subject to shareholders'
approval at a general meeting expected to take place on 2 February 2023.

Turner Pope Broker Offer

ValiRx, a life science company focusing on early-stage cancer therapeutics and
women's health, is pleased to announce that it wishes to provide Existing
Shareholders (as defined below) and other investors who did not participate in
the Fundraising announced today the opportunity to invest in the Company.
Accordingly, under the Placing Agreement, TPI has been granted an option in
the form of a Broker Offer under which TPI will, as agent for the Company,
invite subscriptions for additional new Shares with a value of up to £500,000
at the Issue Price. The maximum number of new Shares to be issued under the
Broker Offer at the Issue Price is 4,545,454. The maximum number of Fundraise
Warrants to be issued under the Broker Offer is 1,136,363.

The Broker Offer opens immediately and will close at 5 p.m. on Monday, 16
January 2023.

As far as is practical, participation in the Broker Offer will be prioritised
for shareholders (direct or indirect) on the register of members of the
Company at the close of business on 12 January 2023 ("Existing
Shareholders").  If the expected maximum subscription under the Broker Offer
is taken up, it will raise an additional £500,000, before expenses.

Existing Shareholders or other interested parties who wish to register their
interest in participating in the Broker Offer should click on the following
TPI platform link:  ValiRx - TPI Broker Offer
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fforms.office.com%2Fe%2F7RAikAA4ce&data=05%7C01%7CAndy.Thacker%40TurnerPope.com%7C661a3e2bef604db39a3708daf4bce817%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638091389746329981%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=UwbJzJD9Jblz9Yk%2FAvdTe1%2FbbvSZ9HZbm1fYBZRS0vk%3D&reserved=0)
(URL: https://forms.office.com/e/7RAikAA4ce)

A further announcement will be made following the end of the period during
which the Broker Offer is open. If the Broker Offer is not fully subscribed by
5 p.m. on 16 January 2023, orders from eligible investors will be satisfied in
full, and the balance of the Broker Offer shall lapse.

General Meeting

Completion of the Broker Offer is conditional on the Fundraising Resolutions
being passed at the General Meeting, which is expected to take place on 2
February 2023. Admission of the Broker Offer Shares is expected on or around 6
February 2023. Further detail on the General Meeting and key dates for
admission of Broker Offer Shares to trading on AIM are contained in the RNS
detailing the Fundraising, also issued today, and will be available in the
Circular to be published to the Company's website www.valirx.com

Capitalised terms used in this announcement shall, unless otherwise defined,
have the same meanings as set out in the Company's announcement also issued
today.

For more information, please contact:

 ValiRx plc                                        Tel: +44 (0) 2476 796496

  Dr Suzanne Dilly, CEO                            www.valirx.com (http://www.valirx.com/)

                                                   Suzanne.Dilly@valirx.com
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

  Liam Murray/Jo Turner/Ludovico Lazzaretti
 Turner Pope Investments (Joint Broker)            Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOESFASFDEDSEFF